Rameen Kasana
2 min read
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) while maintaining a price target of $52.00, citing the strength of the company in keeping more cash than debt. This impressive upside of 186.3%, from the current price of $18.02, shows that the giant is heading north as it develops lead drug candidate DNTH103.
The discussion revolved around the design of DNTH103 and its anticipated Phase 2 trial results for myasthenia gravis (MG), which is expected in September 2025. The management believes the success of DNTH103, relative to C5 inhibitors in the MG trial, would translate to the success of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), driven by the drug’s improved safety profile and straightforward dosing schedule through a biweekly autoinjector.
A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics.
Big changes are expected in the near future. The company is working to test DNTH103 in chronic inflammatory demyelinating polyneuropathy (CIDP), with interim results forecasted for the second quarter of 2026. If the MG trial goes well, this study will clear the path for a follow-up Biologics License Application.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH), founded in 2019, is a New York-based clinical-stage biotechnology company that develops complement therapeutics for patients living with autoimmune and inflammatory diseases. With a commitment to leverage selectivity in its treatments, the company is conducting clinical trials with DNTH103 in several indications.
While we acknowledge the potential of DNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
